Results 191 to 200 of about 74,377 (332)
Cannabinoid Receptor 2 (CB2) in Macrophages: A Promising Clinical Target for Immune Disorders. [PDF]
Yoon HH, Grimsey NL.
europepmc +1 more source
Cannabidiol (CBD) is approved as an adjunctive treatment of seizures associated with Dravet syndrome, Lennox–Gastaut Syndrome, and tuberous sclerosis. Its therapeutic and adverse effects are thought to arise, at least partly, from a pharmacokinetic interaction with clobazam, another anti‐seizure medication (ASM).
Andriy A. Gorbenko +7 more
wiley +1 more source
Synthesis and Pharmacological Characterization of a Novel Cannabinoid Receptor 1 Antagonist. [PDF]
Bengoetxea de Tena I +13 more
europepmc +1 more source
Toxicological and Structural Features of Organophosphorus and Organosulfur Cannabinoid CB1 Receptor Ligands [PDF]
Yoffi Segall
openalex +1 more source
Legalisation of medicinal cannabis leads to an increasing complexity of specific forensic questions. Terpenes, volatile hydrocarbons with modular construction principle of isoprene subunits, are suggested as second substance class alongside phytocannabinoids for classification of cannabis material.
Marica Hundertmark +2 more
wiley +1 more source
Novel floxed cannabinoid receptor 2 mouse line combines knockout capability with dual fluorescent reporters. [PDF]
Laloli KJ +3 more
europepmc +1 more source
Astrocytic ATRX loss causes non‐cell‐autonomous neuronal hyperexcitability. Inducing ATRX deficiency in astrocytes causes selective long‐term memory deficits. Dynamic transcriptomic changes reveal metabolic and synaptic pathway dysregulation. ABSTRACT Astrocytes are increasingly recognized as active regulators of synaptic transmission and memory, yet ...
Miguel A. Pena‐Ortiz +6 more
wiley +1 more source
Cannabigerol Modulates Cannabinoid Receptor Type 2 Expression in the Spinal Dorsal Horn and Attenuates Neuropathic Pain Models. [PDF]
Rezende B +13 more
europepmc +1 more source

